Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome

Cecilia Beatrice Chighizola, Maria Gerosa, Laura Trespidi, Alessio Di Giacomo, Federica Rossi, Barbara Acaia, Pier Luigi Meroni

Research output: Contribution to journalArticlepeer-review

Abstract

Pregnancy morbidity is part of the clinical spectrum of the antiphospholipid syndrome (APS), a chronic autoimmune condition serologically characterized by the persistent positivity of antiphospholipid antibodies (aPL). Antiplatelet and anticoagulant agents are the mainstay of the treatment of obstetric APS. However, there is an ongoing debate about the optimal management of women with most severe aPL-mediated obstetric complications, women not fulfilling APS criteria and those with refractory disease. Unfortunately, the literature cannot provide definite answers to these controversial issues, being flawed by many limitations. The evidence supporting the recommended therapeutic management of different aPL-related obstetrical clinical manifestations is presented, with a critical appraisal of each approach.

Original languageEnglish
Pages (from-to)1505-1517
Number of pages13
JournalExpert Review of Clinical Immunology
Volume10
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Keywords

  • antiphospholipid antibodies
  • antiphospholipid syndrome
  • outcomes
  • pregnancy morbidity
  • treatment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome'. Together they form a unique fingerprint.

Cite this